Treatment With CroFab®

Strike Back Early with CroFab® 


fd7dfba0-26c5-4a54-9ac7-176eb48033ba.png

* Efficacy determined using the snakebite severity score (SSS), a validated objective tool for the clinical evaluation of North American pit viper snakebite in adults. The total score reflects patient evaluation on 6 dimensions: cardiovascular system, local wound, gastrointestinal system, hematologic symptoms, pulmonary system, and central nervous system. The higher the total score, the more severe the snakebite.3 Excluding fasciculations or myokymia, which may be refractory to antivenin.2


95% of patients treated with CroFab® showed a clinical response within 1 hour 1


Triple control 1

 
  • Halts local effects: edema, ecchymosis
  • Resolves systemic effects: nausea, vomiting, dizziness, tachycardia 1
  • Reduces coagulation abnormalities: thrombocytopenia, spontaneous bleeding 1


Treat with confidence

 
  • Comprehensive coverage of all US pit viper venoms1
  • A safety profile you can count on 1
  • Recommended by envenomation experts2,8
  • Top-level biosecurity11



Indication

CroFab® Crotalidae Polyvalent Immune Fab (Ovine) is a sheep-derived antivenin indicated for the management of adult and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins.

Important Safety Information

The most common adverse reactions reported in the clinical studies were urticaria, rash and nausea. Adverse reactions involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 12 of the 42 patients. Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment and one patient discontinued CroFab® due to an allergic reaction. Anaphylaxis and hypersensitivity reactions can occur, and patients should be monitored closely during treatment. CroFab® should not be administered to patients with a known history of hypersensitivity to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available.

In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenin), characterized by decreased fibrinogen, decreased platelets and elevated prothrombin time, occurred in approximately half of the patients studied; one patient required rehospitalization and additional antivenin administration. Recurrent coagulopathy may persist for 1 to 2 weeks or more. Patients who experience coagulopathy due to snakebite should be monitored for recurrent coagulopathy for up to 1 week or longer. During this period, the physician should carefully assess the need for re-treatment with CroFab® and use of any type of anticoagulant or anti-platelet drug.

TO REPORT AN ADVERSE REACTION OR FOR 24-HOUR MEDICAL INFORMATION, CALL 1-844-293-0007.